JP2023537318A - 中枢神経系障害の処置のためのキメラタンパク質および使用方法 - Google Patents

中枢神経系障害の処置のためのキメラタンパク質および使用方法 Download PDF

Info

Publication number
JP2023537318A
JP2023537318A JP2023506330A JP2023506330A JP2023537318A JP 2023537318 A JP2023537318 A JP 2023537318A JP 2023506330 A JP2023506330 A JP 2023506330A JP 2023506330 A JP2023506330 A JP 2023506330A JP 2023537318 A JP2023537318 A JP 2023537318A
Authority
JP
Japan
Prior art keywords
dose
chimeric protein
igf
days
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023506330A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022026902A5 (https=
JP2023537318A5 (https=
Inventor
ジェイ ファフ，サミュエル
ジャン，ヤン
エム クッチェンベッカー，クリストファー
エス チャウラ，ラクミル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silver Creek Pharmaceuticals Inc
Original Assignee
Silver Creek Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silver Creek Pharmaceuticals Inc filed Critical Silver Creek Pharmaceuticals Inc
Publication of JP2023537318A publication Critical patent/JP2023537318A/ja
Publication of JPWO2022026902A5 publication Critical patent/JPWO2022026902A5/ja
Publication of JP2023537318A5 publication Critical patent/JP2023537318A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023506330A 2020-07-30 2021-07-30 中枢神経系障害の処置のためのキメラタンパク質および使用方法 Pending JP2023537318A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063058888P 2020-07-30 2020-07-30
US63/058,888 2020-07-30
PCT/US2021/044019 WO2022026902A2 (en) 2020-07-30 2021-07-30 Chimeric proteins and methods of use for treatment of central nervous system disorders
US17/390,206 US20220031812A1 (en) 2020-07-30 2021-07-30 Chimeric Proteins and Methods of Use for Treatment of Central Nervous System Disorders
US17/390,206 2021-07-30

Publications (3)

Publication Number Publication Date
JP2023537318A true JP2023537318A (ja) 2023-08-31
JPWO2022026902A5 JPWO2022026902A5 (https=) 2024-08-05
JP2023537318A5 JP2023537318A5 (https=) 2024-08-05

Family

ID=80002512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023506330A Pending JP2023537318A (ja) 2020-07-30 2021-07-30 中枢神経系障害の処置のためのキメラタンパク質および使用方法

Country Status (8)

Country Link
US (2) US20220031812A1 (https=)
EP (1) EP4188410B1 (https=)
JP (1) JP2023537318A (https=)
CN (1) CN116917482A (https=)
AU (1) AU2021319203A1 (https=)
CA (1) CA3187734A1 (https=)
ES (1) ES3061325T3 (https=)
WO (1) WO2022026902A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023512423A (ja) 2019-12-24 2023-03-27 ジュベナ・セラピューティクス・インコーポレイテッド 再生性ポリペプチドおよびその使用
KR20240029031A (ko) 2021-06-21 2024-03-05 쥬베나 테라퓨틱스, 인크. 재생 폴리펩티드 및 이의 용도
WO2023159067A2 (en) * 2022-02-15 2023-08-24 Silver Creek Pharmaceuticals, Inc. Chimeric proteins for treatment of acute radiation syndrome
EP4658295A2 (en) * 2023-02-02 2025-12-10 Silver Creek Pharmaceuticals, Inc. Methods of treatment using igf-1 chimeric proteins
CN116549667B (zh) * 2023-05-29 2024-02-09 四川普锐特药业有限公司 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018538356A (ja) * 2015-10-02 2018-12-27 シルバー・クリーク・ファーマシューティカルズ・インコーポレイテッドＳｉｌｖｅｒ Ｃｒｅｅｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 組織修復のための二重特異性治療用タンパク質

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
JP5577098B2 (ja) * 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
CN105524176B (zh) * 2010-05-21 2021-03-19 银溪制药股份有限公司 双特异性融合蛋白
BR112012029611A2 (pt) 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico
DK2699598T3 (en) * 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018538356A (ja) * 2015-10-02 2018-12-27 シルバー・クリーク・ファーマシューティカルズ・インコーポレイテッドＳｉｌｖｅｒ Ｃｒｅｅｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 組織修復のための二重特異性治療用タンパク質

Also Published As

Publication number Publication date
EP4188410A2 (en) 2023-06-07
EP4188410B1 (en) 2025-11-05
AU2021319203A1 (en) 2023-03-02
CN116917482A (zh) 2023-10-20
ES3061325T3 (en) 2026-04-01
US20260041738A1 (en) 2026-02-12
CA3187734A1 (en) 2022-02-03
WO2022026902A2 (en) 2022-02-03
US20220031812A1 (en) 2022-02-03
WO2022026902A3 (en) 2022-03-10
EP4188410A4 (en) 2024-10-02

Similar Documents

Publication Publication Date Title
US20260041738A1 (en) Chimeric Proteins and Methods of Use for Treatment of Central Nervous System Disorders
JP6401057B2 (ja) 虚血のための組み合わせ療法
US9433685B2 (en) Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
KR20140108266A (ko) 지주막하 출혈 및 허혈에 대한 치료법
US20230055441A1 (en) Plasmin-resistant peptides for treating stroke and related conditions
KR20230141958A (ko) 개선된 치료 지수를 위한 플라스민-내성 펩티드
JP2024113090A (ja) 神経可塑性を誘導するための方法および組成物
US20240245756A1 (en) Chimeric proteins and methods of use for treatment of neurodegenerative disorders
WO2022125548A1 (en) Growth and differentiation factor 15 for treatment of proliferative vitreoretinopathy therapy
US20250144175A1 (en) Chimeric proteins for treatment of acute radiation syndrome
US8629242B2 (en) Methods of inhibiting calcineurin with ApoE analogs
JP2026504449A (ja) Ｉｇｆ－１キメラタンパク質を使用する治療方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260421